KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Receivables for 4 consecutive years, with $1.2 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Receivables fell 98.92% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Sep 2023, down 98.92%, and an annual FY2022 reading of $80.9 million, down 40.57% over the prior year.
  • Receivables was $1.2 million for Q3 2023 at Ginkgo Bioworks Holdings, up from $899000.0 in the prior quarter.
  • Across five years, Receivables topped out at $178.1 million in Q2 2022 and bottomed at $899000.0 in Q2 2023.
  • Average Receivables over 4 years is $83.6 million, with a median of $82.9 million recorded in 2022.
  • The sharpest move saw Receivables soared 521.48% in 2021, then plummeted 99.5% in 2023.
  • Year by year, Receivables stood at $21.9 million in 2020, then skyrocketed by 521.48% to $136.1 million in 2021, then tumbled by 40.57% to $80.9 million in 2022, then tumbled by 98.46% to $1.2 million in 2023.
  • Business Quant data shows Receivables for DNA at $1.2 million in Q3 2023, $899000.0 in Q2 2023, and $84.8 million in Q1 2023.